LGMN, His, Human

LGMN, His, Human

Recently, functional studies have demonstrated that legumain (LGMN) cleaves both amyloid β-protein precursor and tau, promoting senile plaques and formation of neurofibrillary tangles, which may play a crucial role in the pathogenesis of Alzheimer's disease (AD). In single-variant association analysis, none of the common variants in LGMN were statistically significant. In gene-based analysis, the LGMN gene also showed no association with AD.
Z05573
¥53,298.00

Ask us a question
Product Introduction
Species Human
Protein Construction
His LGMN (Val18-Tyr433)
Accession # Q99538-1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 48.6 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 55-65 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 50mM Tris, 50mM NaCl, 10% glycerol (pH 7.5).
Concentration Verified by one or more methods from A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.

Background
Target Background Recently, functional studies have demonstrated that legumain (LGMN) cleaves both amyloid β-protein precursor and tau, promoting senile plaques and formation of neurofibrillary tangles, which may play a crucial role in the pathogenesis of Alzheimer's disease (AD). In single-variant association analysis, none of the common variants in LGMN were statistically significant. In gene-based analysis, the LGMN gene also showed no association with AD.
Synonyms Legumain; Prsc1; AEP; LGMN; LGMN1; AI746452; AU022324

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.